Pancreatic Cancer Research

ResearcherUniversity of PittsburghNo recent work listed

Ghislaine Scélo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2692-8507; OpenAlex author ID A5046671345. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
104
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: 8 papers · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 24

  1. Pre-existing psychological disorders, diabetes, and pancreatic cancer: A population-based study of 38,952 Finns. Co-author DOI 10.1016/j.canep.2022.102307↗
  2. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  3. Incorporating multiple sets of eQTL weights into gene-by-environment interaction analysis identifies novel susceptibility loci for pancreatic cancer. Co-author DOI 10.1002/gepi.22348↗
  4. Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA. Co-author DOI 10.1016/j.ebiom.2019.09.042↗
  5. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  6. Gallbladder disease, cholecystectomy, and pancreatic cancer risk in the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1097/cej.0000000000000572↗
  7. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  8. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0091↗
  9. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  10. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  11. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation. Co-author DOI 10.1002/ijc.31900↗
  12. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy126↗
  13. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  14. Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Co-author DOI 10.1158/1055-9965.epi-18-1235↗
  15. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  16. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. Co-author DOI 10.1002/ijc.30790↗
  17. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx004↗
  18. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djw266↗
  19. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  20. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Last author DOI 10.18632/oncotarget.12386↗
  21. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  22. Physical activity and risk of pancreatic cancer in a central European multicenter case-control study. Last author DOI 10.1007/s10552-014-0370-x↗
  23. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Co-author DOI 10.1093/annonc/mdu276↗
  24. Body mass index and body size in early adulthood and risk of pancreatic cancer in a central European multicenter case-control study. Last author DOI 10.1002/ijc.25959↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul Brennan · 9 shared papers, 2011–2020 · strength 0.49
  2. Vladimí­r Janout · 8 shared papers, 2011–2020 · strength 0.40
  3. Eric J. Duell · 6 shared papers, 2014–2020 · strength 0.37
  4. Rachel Ε. Neale · 4 shared papers, 2014–2020 · strength 0.25
  5. Steve Gallinger · 4 shared papers, 2014–2020 · strength 0.25
  6. Paige M. Bracci · 4 shared papers, 2014–2020 · strength 0.25
  7. Gloria M. Petersen · 4 shared papers, 2014–2020 · strength 0.25
  8. Pekka Martikainen · 1 shared paper, 2023 · strength 0.24
  9. Peng Li · 1 shared paper, 2023 · strength 0.24
  10. Harvey A. Risch · 3 shared papers, 2019–2020 · strength 0.23
  11. Donghui Li · 3 shared papers, 2019–2020 · strength 0.23
  12. H. Bas Bueno-de-Mesquita · 4 shared papers, 2014–2020 · strength 0.21
  13. Robert C. Kurtz · 3 shared papers, 2014–2020 · strength 0.18
  14. Sara H. Olson · 3 shared papers, 2014–2020 · strength 0.18
  15. Samir Hanash · 3 shared papers, 2017–2019 · strength 0.17
  16. Anirban Maitra · 3 shared papers, 2017–2019 · strength 0.17
  17. Verena Andrea Katzke · 3 shared papers, 2017–2020 · strength 0.17
  18. Núria Malats · 2 shared papers, 2020 · strength 0.16
  19. Rayjean J. Hung · 2 shared papers, 2019–2020 · strength 0.15
  20. Malin Sund · 2 shared papers, 2019–2020 · strength 0.15
  21. Herbert Yu · 2 shared papers, 2019–2020 · strength 0.14
  22. Alison P. Klein · 2 shared papers, 2019–2020 · strength 0.14
  23. Florence Le Calvez‐Kelm · 2 shared papers, 2016–2020 · strength 0.14
  24. Federico Canzian · 2 shared papers, 2019–2020 · strength 0.13
  25. Michela Capello · 2 shared papers, 2017–2019 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.